Aerpio Pharmaceuticals (OTCMKTS:ARPO) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Aerpio Pharmaceuticals (OTCMKTS:ARPO) in a research report sent to investors on Wednesday, June 12th, BenzingaRatingsTable reports. The firm issued a neutral rating and a $1.00 target price on the stock.

ARPO has been the topic of a number of other reports. Zacks Investment Research raised Aerpio Pharmaceuticals from a hold rating to a buy rating and set a $1.25 target price on the stock in a report on Tuesday, April 9th. National Securities cut Aerpio Pharmaceuticals from a buy rating to a neutral rating in a report on Monday, March 18th. Guggenheim cut Aerpio Pharmaceuticals from a buy rating to a neutral rating in a report on Monday, March 18th. Finally, Cantor Fitzgerald set a $8.00 price target on Aerpio Pharmaceuticals and gave the company a buy rating in a report on Tuesday, March 5th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Aerpio Pharmaceuticals presently has a consensus rating of Hold and an average price target of $6.05.

ARPO traded up $0.01 during midday trading on Wednesday, reaching $0.90. 104,486 shares of the company’s stock traded hands, compared to its average volume of 368,533. The firm has a fifty day moving average price of $0.98. Aerpio Pharmaceuticals has a 52 week low of $0.85 and a 52 week high of $4.35.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01.

In related news, major shareholder Bioventures Ltd Novartis sold 200,746 shares of Aerpio Pharmaceuticals stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $1.07, for a total value of $214,798.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 1,201,337 shares of company stock valued at $1,242,015 in the last quarter. Company insiders own 38.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Alambic Investment Management L.P. purchased a new stake in Aerpio Pharmaceuticals during the 1st quarter worth approximately $85,000. Jane Street Group LLC increased its stake in Aerpio Pharmaceuticals by 216.3% during the 4th quarter. Jane Street Group LLC now owns 81,984 shares of the company’s stock worth $139,000 after buying an additional 56,065 shares in the last quarter. HarbourVest Partners LLC purchased a new stake in Aerpio Pharmaceuticals during the 4th quarter worth approximately $246,000. Citigroup Inc. purchased a new stake in Aerpio Pharmaceuticals during the 4th quarter worth approximately $411,000. Finally, Bank of New York Mellon Corp purchased a new stake in Aerpio Pharmaceuticals during the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 0.37% of the company’s stock.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

See Also: What is the QQQ ETF?

Analyst Recommendations for Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.